- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06568939
Исследование по оценке побочных эффектов и того, как введенный внутривенно (IV) телизотузумаб ведотин (ABBV-399) перемещается по организму в качестве монотерапии у взрослых участников с ранее леченным неплоскоклеточным немелкоклеточным раком легких (НМРЛ)
Фаза 2, открытое, рандомизированное, глобальное исследование двух режимов терапии телизотузумабом ведотином у пациентов с ранее леченными сверхэкспрессией c-Met, диким типом EGFR, локально-распространенным/метастатическим неплоскоклеточным немелкоклеточным раком легких
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Контакты исследования
- Имя: ABBVIE CALL CENTER
- Номер телефона: 844-663-3742
- Электронная почта: abbvieclinicaltrials@abbvie.com
Места учебы
-
-
-
São Paulo, Бразилия, 01323-020
- Рекрутинг
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza, Ceará, Бразилия, 60810-180
- Рекрутинг
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba, Paraná, Бразилия, 80510-130
- Рекрутинг
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém, Pará, Бразилия, 66063-495
- Рекрутинг
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife, Pernambuco, Бразилия, 50040-000
- Рекрутинг
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Бразилия, 59075-740
- Рекрутинг
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Бразилия, 98700-000
- Рекрутинг
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Бразилия, 88020-210
- Рекрутинг
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
-
Haifa, Израиль, 3109601
- Рекрутинг
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem, Израиль, 9103102
- Завершенный
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava, Central District, Израиль, 4428164
- Рекрутинг
- Meir Medical Center /ID# 270071
-
Petah Tikva, Central District, Израиль, 4941492
- Рекрутинг
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Израиль, 5265601
- Рекрутинг
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 101149
- Рекрутинг
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou, Fujian, Китай, 350014
- Рекрутинг
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning, Guangxi, Китай, 530021
- Рекрутинг
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin, Heilongjiang, Китай, 150081
- Рекрутинг
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou, Henan, Китай, 450008
- Рекрутинг
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan, Hubei, Китай, 430022
- Рекрутинг
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 330006
- Рекрутинг
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an, Shaanxi, Китай, 710061
- Рекрутинг
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi, Shandong, Китай, 276001
- Рекрутинг
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi, Xinjiang, Китай, 830011
- Рекрутинг
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
Beograd
-
Belgrade, Beograd, Сербия, 11000
- Рекрутинг
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade, Beograd, Сербия, 11080
- Рекрутинг
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade, Beograd, Сербия, 11000
- Рекрутинг
- University Clinical Center Serbia /ID# 270808
-
Belgrade, Beograd, Сербия, 11000
- Рекрутинг
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš, Nisavski Okrug, Сербия, 18300
- Рекрутинг
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz, Sremski Okrug, Сербия, 21208
- Рекрутинг
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac, Sumadijski Okrug, Сербия, 34000
- Рекрутинг
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Сингапур, 169611
- Рекрутинг
- National Cancer Centre Singapore /ID# 271499
-
Singapore, Central Singapore, Сингапур, 119074
- Рекрутинг
- National University Hospital /ID# 271700
-
-
-
-
Arizona
-
Chandler, Arizona, Соединенные Штаты, 85224
- Рекрутинг
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72205
- Рекрутинг
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90067
- Рекрутинг
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles, California, Соединенные Штаты, 90025
- Рекрутинг
- Start Los Angeles /ID# 284999
-
Oxnard, California, Соединенные Штаты, 93030
- Рекрутинг
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06510
- Завершенный
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32256
- Рекрутинг
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala, Florida, Соединенные Штаты, 34474
- Рекрутинг
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines, Florida, Соединенные Штаты, 33028
- Рекрутинг
- Memorial Hospital West /ID# 270313
-
St. Petersburg, Florida, Соединенные Штаты, 33701-4732
- Рекрутинг
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg, Florida, Соединенные Штаты, 33705
- Рекрутинг
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach, Florida, Соединенные Штаты, 33401
- Рекрутинг
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens, Georgia, Соединенные Штаты, 30607
- Рекрутинг
- University Cancer and Blood Center /ID# 270969
-
Marietta, Georgia, Соединенные Штаты, 30060
- Рекрутинг
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah, Georgia, Соединенные Штаты, 31404
- Завершенный
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96819
- Рекрутинг
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60607
- Рекрутинг
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles, Illinois, Соединенные Штаты, 60714
- Рекрутинг
- Illinois Cancer Specialists /ID# 274678
-
Peoria, Illinois, Соединенные Штаты, 61637-0001
- Рекрутинг
- OSF St. Francis Medical Center /ID# 281591
-
Springfield, Illinois, Соединенные Штаты, 62702
- Рекрутинг
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln, Nebraska, Соединенные Штаты, 68506
- Рекрутинг
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha, Nebraska, Соединенные Штаты, 68130
- Рекрутинг
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno, Nevada, Соединенные Штаты, 89502
- Рекрутинг
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick, New Jersey, Соединенные Штаты, 08816-4096
- Рекрутинг
- Astera Cancer Care /ID# 272359
-
Teaneck, New Jersey, Соединенные Штаты, 07666
- Рекрутинг
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx, New York, Соединенные Штаты, 10461
- Рекрутинг
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury, New York, Соединенные Штаты, 11590
- Рекрутинг
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst, North Carolina, Соединенные Штаты, 28374
- Рекрутинг
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg, Ohio, Соединенные Штаты, 43551
- Рекрутинг
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville, Ohio, Соединенные Штаты, 43701
- Рекрутинг
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre, Pennsylvania, Соединенные Штаты, 18840
- Рекрутинг
- Guthrie Robert Packer Hospital /ID# 270316
-
York, Pennsylvania, Соединенные Штаты, 17403
- Рекрутинг
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Рекрутинг
- Medical University of South Carolina /ID# 273272
-
Greenville, South Carolina, Соединенные Штаты, 29607
- Рекрутинг
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Рекрутинг
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75246
- Рекрутинг
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler, Texas, Соединенные Штаты, 75702
- Рекрутинг
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden, Utah, Соединенные Штаты, 84405
- Рекрутинг
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Рекрутинг
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane, Washington, Соединенные Штаты, 99208
- Рекрутинг
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma, Washington, Соединенные Штаты, 98405
- Рекрутинг
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 466-8560
- Рекрутинг
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi, Chiba, Япония, 277-8577
- Рекрутинг
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 060-8648
- Рекрутинг
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe, Hyōgo, Япония, 650-0046
- Рекрутинг
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Япония, 252-0375
- Рекрутинг
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai, Miyagi, Япония, 981-0914
- Рекрутинг
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki, Miyazaki, Япония, 889-1692
- Рекрутинг
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, Япония, 710-8602
- Рекрутинг
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda, Shizuoka, Япония, 426-0077
- Рекрутинг
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama, Wakayama, Япония, 641-8510
- Рекрутинг
- Wakayama Medical University Hospital /ID# 276997
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Другие имена:
|
|
Экспериментальный: Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Другие имена:
|
|
Экспериментальный: Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Временное ограничение: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Временное ограничение: Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Временное ограничение: Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Временное ограничение: Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Временное ограничение: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Временное ограничение: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
Временное ограничение: Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Временное ограничение: Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Временное ограничение: Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Временное ограничение: Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Временное ограничение: Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Временное ограничение: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Временное ограничение: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
Временное ограничение: Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
Временное ограничение: Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Временное ограничение: Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: ABBVIE INC., AbbVie
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- M25-274
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Сроки обмена IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Критерии совместного доступа к IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .